Trials / Terminated
TerminatedNCT04730427
Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19
A Phase 1b Study to Investigate the Safety and Preliminary Efficacy of GX-I7 in Patients With COVID-19
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Genexine, Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase 1b clinical trial to investigate the safety and preliminary effects of a single dose of a test drug or placebo to the subjects who has diagnosed as COVID-19 infection.
Detailed description
This study is a phase 1b clinical trial to investigate the safety and preliminary effects of a single dose of a test drug or placebo to the subjects who has diagnosed as COVID-19 infection. Study design: prospective, randomized, placebo-controlled, single-blind, single-center
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GX-I7 | Recombinant human interleukin-7 hybrid Fc |
| DRUG | GX-I7 vehicle | Formulation buffer of recombinant human interleukin-7 hybrid Fc |
Timeline
- Start date
- 2021-03-24
- Primary completion
- 2022-05-08
- Completion
- 2022-07-07
- First posted
- 2021-01-29
- Last updated
- 2022-11-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04730427. Inclusion in this directory is not an endorsement.